Search company, investor...

iMediSync

imedisync.com

Founded Year

2012

Stage

Series B | Alive

Total Raised

$8.44M

Last Raised

$4.11M | 3 yrs ago

About iMediSync

iMediSync develops iSyncBrain, a cloud-based artificial intelligence EEG analysis platform for the early detection and treatment of dementia, cognitive disorders, depression, addiction, attention deficit hyperactivity disorder (ADHD), and other various conditions.

Headquarters Location

175, Yeoksam-ro, Gangnam-gu 5F

Seoul, 06247,

South Korea

+82-2-747-7422

Missing: iMediSync's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: iMediSync's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing iMediSync

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iMediSync is included in 5 Expert Collections, including Mental Health Tech.

M

Mental Health Tech

1,267 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

M

Medical Devices

8,567 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

C

Conference Exhibitors

5,302 items

D

Digital Health

13,118 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

H

Health IT

7,901 items

iMediSync Patents

iMediSync has filed 1 patent.

The 3 most popular patent topics include:

  • Electroencephalography
  • Artificial intelligence
  • Artificial neural networks
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/7/2020

Neurological disorders, Evoked potentials, Transcription factors, Electroencephalography, Epidemiology

Application

Application Date

5/7/2020

Grant Date

Title

Related Topics

Neurological disorders, Evoked potentials, Transcription factors, Electroencephalography, Epidemiology

Status

Application

Latest iMediSync News

iMediSync Leads Global Remote Healthcare Market With Its AI-Based Brain Scanning Device iSyncWave

May 13, 2022

Download Loading media player... iMediSync participated in Kotra’s Innovative Global Startups Showcase. iSyncWave, an innovative AI-based brain-scanning device developed by iMediSync, gained global media attention during the event. It is the world’s first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device. iMediSync participated in Kotra’s Innovative Global Startups Showcase. iSyncWave, an innovative AI-based brain-scanning device developed by iMediSync, gained global media attention during the event. It is the world’s first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device. SEOUL, South Korea--( BUSINESS WIRE )-- iMediSync announced it participated in Kotra’s “Innovative Global Startups Showcase.” As the COVID-19 pandemic has triggered a mental health crisis such as ‘Corona Blue’ around the globe, mental health has become an important issue. Early diagnosis is critical for discovering mental illnesses such as Alzheimer's Dementia or clinical depression for better prognosis and as a cost-cutting measure. Aligned with this, iSyncWave , an innovative AI-based brain-scanning device, gained global media attention during the event. iSyncWave is the world’s first integrated wireless EEG measurement and Neurotherapy convergence solution and is a remote-care mental health platform device. The device is a 100 percent dry-type headset equipped with the age/gender matching normative database with 1,300+ healthy brainwaves covering almost all ages. It offers a high-quality EEG/HRV screening and AI automatic predictive analysis of potential MCI conditions in just 10-minute. This system could dramatically reduce time and resources. Also, the device is equipped with PBM (Photobiomodulation) LED therapy to suppress brain cells from dying, which provides personalized therapy protocols that target neuro-related diseases. Meanwhile, after successfully demonstrating iSyncWave at CES 2022, iMediSync has the attention of media and visitors around the world and is receiving numerous collaboration and co-research offers. iSyncWave has also won the 2022 Red Dot Design Award for its innovative and user-friendly design, and it is highly spoken of meeting the convenience needs of clients along with satisfying technology. iMediSync solutions have been used by more than 60 hospitals and clinics within South Korea. Being recognized for its technological prowess, iMediSync was selected for Inspira, Israel's biotechnology investment and development program. iMediSync is actively participating in various studies including joint Research on Promotion of Brain Development in Children and Adolescents through Exercise with Professor John Ratey of the Department of Neuropsychiatry at Harvard Medical School. They are also considering becoming involved in the pharmaceutical industry and developing business relations with various insurance companies and governments in the near future. iMediSync CEO Seung-Wan Kang stated, "We will provide life-changing mental healthcare experiences by introducing neuro-mental illness biomarkers and the patented Electroencephalogram (EEG)/Heart Rate Variability (HRV) technology. iMediSync will leap forward as a trend leader in the field of telemedicine, and AI medicine and digital therapy will take place in a post-Covid-19 era as an optimized personal mental healthcare service provider.” Contacts

iMediSync Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

iMediSync Rank

iMediSync Frequently Asked Questions (FAQ)

  • When was iMediSync founded?

    iMediSync was founded in 2012.

  • Where is iMediSync's headquarters?

    iMediSync's headquarters is located at 175, Yeoksam-ro, Gangnam-gu, Seoul.

  • What is iMediSync's latest funding round?

    iMediSync's latest funding round is Series B.

  • How much did iMediSync raise?

    iMediSync raised a total of $8.44M.

  • Who are the investors of iMediSync?

    Investors of iMediSync include Korea Development Bank, A Ventures, TIPS Program, AJU IB Investment, NHN Investment and 3 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.